New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA Reclassifies Sharps Needle Destruction Device

Agency believes final order will decrease regulatory burden on manufacturers as they will no longer be required to submit a premarket approval application (PMA), but can instead submit a less-burdensome premarket notification (510(k)) before marketing this type of device

Agency believes final order will decrease regulatory burden on manufacturers as they will no longer be required to submit a premarket approval application (PMA), but can instead submit a less-burdensome premarket notification (510(k)) before marketing this type of device. Shown here is a sharps collection container, not a needle destruction device.
Agency believes final order will decrease regulatory burden on manufacturers as they will no longer be required to submit a premarket approval application (PMA), but can instead submit a less-burdensome premarket notification (510(k)) before marketing this type of device. Shown here is a sharps collection container, not a needle destruction device.

FDA issued a final order “General Hospital and Personal Use Devices; Reclassification of Sharps Needle Destruction Device.” Under this final order, the FDA has reclassified the needle destruction device from a class III to a class II device and renamed the device type to sharps needle destruction device.

A sharps needle destruction device is an alternative to conventional sharps/needle disposal containers found in home and hospital settings. These devices are powered by electricity or batteries and they use different technologies such as grinding or incineration to destroy needles and other types of sharps (e.g., lancets).

Based on new information, the FDA has found sufficient information exists to establish special controls that, together with general controls, can provide a reasonable assurance of safety and effectiveness for sharps needle destruction devices. The agency believes this final order will decrease regulatory burden on manufacturers as they will no longer be required to submit a premarket approval application (PMA), but can instead submit a less burdensome premarket notification (510(k)) before marketing this type of device.

The FDA is issuing this final order as part of the Center for Devices and Radiological Health’s 2014-2015 Strategic Priority to “Strike the Right Balance Between Premarket and Postmarket Data Collection.”

The final order can be found by searching for docket number FDA-2017-N-6216 on www.regulations.gov. The final order will be effective starting June 4, 2018.

If you have any questions, please contact the Division of Industry and Consumer Education (DICE) in the Center for Devices and Radiological Health (CDRH) at 1-800-638-2041, 301-796-7100 or at [email protected].

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub
How to Honor a Leader
Induction into the Packaging & Processing Hall of Fame is the highest honor in our industry. Submit your leader to be considered for the Class of 2024 now through June 10th. New members will be inducted at PACK EXPO International in Chicago.
Read More
How to Honor a Leader